NCT02600585View on ClinicalTrials.gov

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

CompletedOBSERVATIONAL
Enrollment

254,648

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Human Influenza
Interventions
BIOLOGICAL

Recombinant Influenza Vaccine

Intramuscular injection of study vaccine

BIOLOGICAL

Inactivated Influenza Vaccine

Intramuscular injection of study vaccine

Trial Locations (1)

94612

Kaiser Permanente Vaccine Study Center, Oakland

All Listed Sponsors
collaborator

Kaiser Permanente

OTHER

lead

Protein Sciences Corporation

INDUSTRY

NCT02600585 - Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults | Biotech Hunter | Biotech Hunter